Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
We plan to provide a further update on this clinical trial when we have additional meaningful patient data.
- We plan to provide a further update on this clinical trial when we have additional meaningful patient data.
- Preliminary data from patients in the clinical trial are expected in the second half of 2023.
- The Phase 1 clinical trial with AB-161 is on-going with single-ascending dose data expected in the second half of 2023.
- We expect to nominate an nsp12 inhibitor clinical candidate and initiate IND-enabling studies in the second half of 2023.